MCID: RFR015
MIFTS: 15

Refractory Anemia with Excess Blasts Type 1

Categories: Blood diseases, Rare diseases

Aliases & Classifications for Refractory Anemia with Excess Blasts Type 1

MalaCards integrated aliases for Refractory Anemia with Excess Blasts Type 1:

Name: Refractory Anemia with Excess Blasts Type 1 58
Refractory Anemia with Excess Blasts I 71
Raeb-1 58

Characteristics:

Orphanet epidemiological data:

58
refractory anemia with excess blasts type 1
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

ICD10 via Orphanet 33 D46.2
UMLS via Orphanet 72 C1318550
Orphanet 58 ORPHA100019
UMLS 71 C1318550

Summaries for Refractory Anemia with Excess Blasts Type 1

MalaCards based summary : Refractory Anemia with Excess Blasts Type 1, also known as refractory anemia with excess blasts i, is related to myelodysplastic syndrome. The drugs Lenograstim and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone marrow and bone.

Related Diseases for Refractory Anemia with Excess Blasts Type 1

Diseases in the Refractory Anemia with Excess Blasts Type 2 family:

Refractory Anemia with Excess Blasts Type 1

Diseases related to Refractory Anemia with Excess Blasts Type 1 via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 myelodysplastic syndrome 10.3

Symptoms & Phenotypes for Refractory Anemia with Excess Blasts Type 1

Drugs & Therapeutics for Refractory Anemia with Excess Blasts Type 1

Drugs for Refractory Anemia with Excess Blasts Type 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 23)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
2
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
3
Sargramostim Approved, Investigational Phase 2, Phase 3 83869-56-1, 123774-72-1
4
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
5
Decitabine Approved, Investigational Phase 3 2353-33-5 451668
6
Azacitidine Approved, Investigational Phase 3 320-67-2 9444
7 Molgramostim Investigational Phase 2, Phase 3 99283-10-0
8 Adjuvants, Immunologic Phase 2, Phase 3
9 Antirheumatic Agents Phase 2, Phase 3
10 Protein Kinase Inhibitors Phase 3
11 ON 01910 Phase 3
12
Lenalidomide Approved Phase 2 191732-72-6 216326
13
Melphalan Approved Phase 2 148-82-3 460612 4053
14 Alkylating Agents Phase 2
15 Immunosuppressive Agents Phase 2
16 Immunologic Factors Phase 2
17 Angiogenesis Inhibitors Phase 2
18
Cytarabine Approved, Experimental, Investigational Phase 1 147-94-4, 65-46-3 6253
19 Antimetabolites Phase 1
20 Anti-Infective Agents Phase 1
21 Antiviral Agents Phase 1
22 Antimitotic Agents Phase 1
23 Aclacinomycins

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Granulocyte Colony-stimulating Factor+Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Patients With RAEB-1, RAEB-2 and AML Secondary to MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Unknown status NCT02744742 Phase 2, Phase 3 Decitabine;Busulfan (BU);Cyclophosphamide (CY);Granulocyte Colony-Stimulating Factor(G-CSF)
2 A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent Recruiting NCT02562443 Phase 3 rigosertib;Any approved or standard-of-care therapy;best supportive care (BSC);best supportive care (BSC)
3 Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine Active, not recruiting NCT01241500 Phase 3 ON 01910.Na
4 A Phase 1/2, Single-Arm Study To Assess The Efficacy and Safety Of 72-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Every Other Week in Patients With Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Completed NCT00854945 Phase 1, Phase 2 ON 01910.Na
5 Revlimid®, and Metronomic Melphalan in the Management of Higher Risk Myelodysplastic Syndromes (MDS) and CMML: A Phase 2 Study" Completed NCT00744536 Phase 2 Lenalidomide and melphalan
6 Phase I Study of 4'-Thio-araC in Patients With Advanced Hematologic Malignancies Completed NCT01139151 Phase 1 3 Day Thiarabine;5 Day Thiarabine
7 A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With RAEB-1 AND RAEB-2 Myelodysplastic Syndrome (MDS) and AML With Trisomy 8 Completed NCT00533416 Phase 1 ON 01910 Na
8 A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes Terminated NCT00458159 Phase 1 CC-11006
9 Effect of Chemotherapy vs No Chemotherapy Pre-transplantation for Patients With RAEB-1, RAEB-2 and AML Secondary to MDS (Bone Marrow Blast Cells Less Than 50%) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Unknown status NCT02850822 Demethylation drug;Chemotherapy regimen

Search NIH Clinical Center for Refractory Anemia with Excess Blasts Type 1

Genetic Tests for Refractory Anemia with Excess Blasts Type 1

Anatomical Context for Refractory Anemia with Excess Blasts Type 1

MalaCards organs/tissues related to Refractory Anemia with Excess Blasts Type 1:

40
Myeloid, Bone Marrow, Bone

Publications for Refractory Anemia with Excess Blasts Type 1

Articles related to Refractory Anemia with Excess Blasts Type 1:

# Title Authors PMID Year
1
Myelodysplastic Syndrome with concomitant t(5;21)(q15;q22) and del(5)(q13q33): case report and review of literature. 61
27358895 2016
2
Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. 61
24440648 2014
3
Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification. 61
22948274 2013
4
[Analysis of immunophenotypic features of blasts in patients with myelodysplastic syndrome by flow cytometry and its diagnostic significance]. 61
22739171 2012
5
Therapy-related myeloid neoplasms following treatment with radioiodine. 61
21993688 2012
6
Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. 61
16270213 2005

Variations for Refractory Anemia with Excess Blasts Type 1

Expression for Refractory Anemia with Excess Blasts Type 1

Search GEO for disease gene expression data for Refractory Anemia with Excess Blasts Type 1.

Pathways for Refractory Anemia with Excess Blasts Type 1

GO Terms for Refractory Anemia with Excess Blasts Type 1

Sources for Refractory Anemia with Excess Blasts Type 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....